查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年阿片类药物引起的便秘治疗的全球市场
市场调查报告书
商品编码
1140766

2022-2029 年阿片类药物引起的便秘治疗的全球市场

Global Opioid Induced Constipation Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期间（2022-2029 年），阿片类药物引起的便秘治疗的市场规模预计将以 4.4% 的复合年增长率增长。

阿片类镇痛剂适用于患有急性和慢性非癌症疼痛的患者。阿片类药物引起的便秘 (OIC) 是一种与长期使用阿片类药物相关的继发性疾病。大约 40% 至 80% 服用阿片类镇痛药的患者可能会出现 OIC。这些药物之所以有效，是因为它们通过与整个神经系统的受体结合来阻断疼痛信号。这些受体也存在于肠道中。

市场动态

全球阿片类药物引起的便秘治疗市场的增长归因于 OIC 患者群的扩大，这是由于阿片类药物在慢性疼痛治疗□□中的使用增加所致。对 OIC 的安全有效治疗的需求也日益增加。

慢性特发性疼痛患病率的增加以及有效 OIC 疗法的增加将推动市场增长。

患者使用吗啡、氢吗啡酮和可待因等阿片类镇痛剂作为非癌性慢性疼痛的处方，严重影响消化系统，导致对 OIC 药物的大量需求。例如，根据疾病控制和预防中心 2021 年 11 月的数据，2019 年 OIC 处方数量增加到 153,260,450 份，到 2020 年增加到 142,816,781 份。因此，阿片类药物使用者数量的增加将需要有效的药物治疗 OIC 疾病，这可能会在预测期内推动阿片类药物引起的便秘市场。预计人口老龄化将对市场产生重大影响，因为 65 岁及以上的人更容易患慢性病。

根据 2021 年世界卫生组织事实，2015 年至 2050 年间，世界 60 岁以上人口的比例预计将翻一番，从 12% 增加到 22%。此外，根据世界卫生组织的数据，到 2030 年，地球上六分之一的人将超过 60 岁。预计 60 岁及以上人口将从 2020 年的 10 亿增长到 2050 年的 14 亿。到 2050 年，世界 60 岁以上的人口将翻一番，达到 21 亿。从 2020 年到 2050 年，80 岁及以上的人口数量预计将增加两倍，达到 4.26 亿。因此，阿片类镇痛剂处方的增加，以及发达国家老年人口的增加，将在预测期内推动市场增长。

患者对 OIC 缺乏认识是市场增长的障碍

但是，对于将 OIC 视为一种综合征并更喜欢普通泻药的患者缺乏认识，以及开发下一代止痛药替代阿片类药物的研究努力可能会阻碍市场增长。.

COVID-19 影响分析

COVID-19 影响了全球药品供应链，并对阿片类药物引起的便秘治疗市场产生了积极影响。大剂量和长期使用阿片类药物会损害免疫系统功能并使 COVID-19 疾病的病程复杂化。在 COVID-19 的不同阶段，抑制某些免疫反应的潜力可能对药物的预防、临床支持和治疗使用很重要。

细分分析

预计 mu 阿片受体拮抗剂细分市场在预测期内（2022-2029 年）将以最快的复合年增长率增长。

预计 Mu 阿片受体拮抗剂将在预测期内占据很大的收入份额。这种主导地位归因于主要参与者推出了适用于不同 OIC 症状的不同类型的产品，以及该领域研究活动的增加。

市场上现成的用于 OIC 适应症的药物包括甲基纳曲酮 (Relistor)、Naldemedine (Symproic)、Naloxegol (Movantik) 和 Alvimopan (Entereg)。甲基纳曲酮被研究并批准用于晚期癌症疼痛和其他疾病的患者，而 Alvimopan 和 Naloxegol 则用于非癌症患者。因此，预计 mu 阿片受体拮抗剂的可用性增加将推动预测期内的细分市场增长。

此外，2021 年 2 月，RedHill Biopharma Ltd. 与 Cosmo Pharmaceuticals NV 合作，与 Movantik（一种 fosi-阿片受体拮抗剂）合作，目前是非结核病肺 (NTM) 的单药一线口服给药。签订了生产两种先导产品 RHB-204 的协议，该产品正处于美国第三阶段试验中，作为一种治疗方法。这些因素正在推动预测期内的市场增长。

区域分析

北美在全球阿片类药物引起的便秘治疗市场中占有最大的市场份额

预计北美将在整个预测期内主导阿片类药物引起的便秘市场。这一优势归因于美国老年患者中各种胃肠道疾病的患病率不断增加，以及加拿大最近阿片类药物的消费量激增。根据 2020 年疾病控制和预防中心的数据，在美国，2020 年阿片类药物的总体配药率为每 100 人 43.3 个处方。因此，美国 OIC 处方数量的增加将在预测期内启动市场。

此外，根据 2020 年 6 月发表在《未来医学》(Future Medicine) 上的 Naldemedine 用于治疗患有慢性非癌性疼痛的成人阿片类药物引起的便秘的研究，Naldemedine 用于治疗患有慢性非癌性疼痛的成人阿片类药物引起的便秘。似乎是治疗性便秘的有效且安全的一线治疗方法。因此，预计该国增加产品开发和多项临床试验将推动该地区的市场。

竞争格局

阿片类药物引起的便秘治疗市场与本地和全球公司竞争适度。为市场增长做出贡献的主要参与者包括阿斯利康 (AstraZeneca) plc、Mallinckrodt Pharmaceuticals、Bausch Health (Salix Pharmaceuticals)、默克公司、Shionogi &Co Ltd、葛兰素史克 (Theravance Biopharma Inc)、武田製药、诺华製药 (Sandoz)，包括 RedHill Biopharma、辉瑞, Inc. 等。主要参与者采取了多种增长战略，例如产品发布、收购和合作伙伴关係，这些战略为全球阿片类药物引起的便秘治疗市场的增长做出了贡献。例如，2022 年 1 月，BioGaia Pharma 报告了第一位患者参加了 2 期临床试验 (OIC-1)，该试验评估了 BGP345A 用于治疗阿片类药物引起的便秘。

阿斯利康公司

概述

公司专注于心血管、肾臟/代谢、呼吸/免疫等肿瘤学和生物製药领域处方药的发现、开发和商业化。这些药物是製造、销售和销售的。

产品组合

MOVANTIK：MOVANTIK 是一种处方药，用于治疗由称为阿片类药物的处方止痛药引起的成人便秘，并伴有非活动性癌症引起的长期（慢性）疼痛。

本购入理由

  • 按药物类别、给药途径、分销渠道和地理区域可视化全球阿片类药物诱发便秘治疗市场的构成，突出关键商业资产和参与者。
  • 分析全球阿片类药物引起的便秘治疗市场的趋势和联合开发项目，以确定商机。
  • Excel 数据表包含全球阿片类药物引起的便秘治疗市场 4/5 级细分市场的数千个数据点。
  • 通过详尽的定性访谈和深入的市场调查，获得一份包含最相关分析的冷静 PDF 报告。
  • 在 Excel 中为所有主要市场参与者的主要产品创建产品地图

全球阿片类药物诱发的便秘治疗市场报告将提供对大约 40 多个市场数据表、45 多个图表和大约 180-200 页的范围的访问。

观众

  • 服务提供商/买方
  • 行业投资者/投资银行家
  • 教育和研究机构
  • 调查员
  • 初创公司
  • 製造

内容

第 1 章阿片类药物引起的便秘治疗的全球市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章阿片类药物引起的便秘治疗的全球市场-市场定义和概述

第 3 章阿片类药物引起的便秘治疗的全球市场 - 执行摘要

  • 市场细分：按药物类别
  • 按管理途径划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章阿片类药物引起的便秘治疗的全球市场 - 市场动态

  • 市场影响因素
    • 驱动程序
      • 增加了有效的 OIC 疗法的可用性
      • 由于慢性特发性疼痛的患病率上升，有效的 OIC 疗法的可用性增加
    • 限制因素
      • 患者对 OIC 的认识不足
    • 商机
    • 影响分析

第 5 章阿片类药物引起的便秘治疗的全球市场 - 行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章阿片类药物引起的便秘治疗的全球市场 - COVID-19 分析

  • 对 COVID-19 市场的分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的定价动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章。全球阿片类药物引起的便秘治疗市场 - 按药物类别

  • μ阿片受体拮抗剂
    • 甲基纳曲酮
    • 纳洛昔戈
    • 纳尔多津
    • 其他
  • 氯离子通道活化剂
    • 鲁比前列酮
    • 其他

第 8 章全球阿片类药物引起的便秘治疗市场 - 按管理途径

  • 口语
  • 肠胃外

第 9 章。阿片类药物引起的便秘治疗的全球市场：按分销渠道划分

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 10 章全球阿片类药物引起的便秘治疗市场：按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章治疗阿片类药物引起的便秘的全球市场 - 竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章阿片类药物引起的便秘治疗的全球市场 - 公司简介

  • 阿斯利康公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Mallinckrodt Pharmaceuticals
  • Bausch Heath（Salix Pharmaceuticals）
  • Merck & Co Inc
  • Shionogi & Co Ltd
  • GlaxoSmithKline（Theravance Biopharma Inc）
  • Takeda Pharmaceutical
  • Novartis AG（Sandoz）
  • Cubist Pharmaceuticals
  • Pfizer, Inc.

第13章 阿片类药物引起的便秘治疗的全球市场-DataM

简介目录
Product Code: DMPH1

Market Overview

Opioid-Induced Constipation Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 4.4% during the forecast period (2022-2029).

Opioid analgesics are prescribed to patients with acute and chronic non-cancer pain. Opioid-induced constipation (OIC) is a type of secondary illness associated with the prolonged use of opioids. Approximately 40%-80% of patients receiving opioid analgesics may experience OIC. These medications are effective because they block pain signals by attaching to receptors throughout the nervous system. These receptors are also found in bowels.

Market Dynamics

The global opioid-induced constipation treatment market growth is driven by an expanding base of OIC sufferers as a result of the increased use of opioids in the treatment of chronic pain. Also, there is a vast unmet need in the market for highly-targeted, safe, and efficient therapeutic options for OIC management.

The rise in the availability of effective OIC drugs along with the growing prevalence of chronic idiopathic pains will drive the market growth

The patients use opioid analgesics such as morphine, hydromorphone, codeine, and others as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153,260,450 in 2019 and 142,816,781 in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for the OIC ailments which is likely to fuel the Opioid-Induced Constipation market over the forecast period. The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases.

According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, the increasing use of opioid analgesic prescriptions along with the growing geriatric population in developed nations will drive the market growth in the forecast period.

Lack of awareness about OIC among the patients will hamper the growth of the market

However, lack of awareness about OIC among the patients considering it as a syndrome resulting in a preference for general laxatives and ongoing research activities to develop next-generation analgesics to replace opioids are likely to hamper the market growth.

COVID-19 Impact Analysis

COVID-19 impacted the global supply chain of pharmaceuticals, positively affecting the opioid-induced constipation treatment market. Opioid use at high doses and for long periods of time can impair immune system function, complicating the course of COVID-19 disease. In various stages of the COVID-19, potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications.

Segment Analysis

The mu-opioid receptor antagonists segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The Mu-opioid receptor antagonists are expected to account for a large revenue share over the forecast period. This dominance is owing to the availability of various types of products launched by the key players that are suitable for various symptoms in the OIC and the rise in research activities in the segment.

A few of the drugs that are readily available in the market for OIC indication are Methylnaltrexone (Relistor), Naldemedine (Symproic), Naloxegol (Movantik), and Alvimopan (Entereg). Methylnaltrexone was studied and approved for patients with advanced cancer pain or other diseases, whereas Alvimopan and Naloxegol were for non-cancer patients. Thus increasing availability of Mu-opioid Receptor Antagonists anticipated the segment growth over the forecast period.

Furthermore, in February 2021, RedHill Biopharma Ltd. signed agreements with Cosmo Pharmaceuticals NV to manufacture two key products; Movantik(μ-opioid receptor antagonist), and RHB-204, currently in a Phase 3 United States study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. These factors are driving the growth of the market in the forecast period.

Geographical Analysis

The North American region holds the largest market share of the global opioid-induced constipation treatment market

North America is expected to dominate the opioid-induced constipation market throughout the forecast period. Dominance is due to the growing prevalence of various GI disorders among geriatric patients in the United States and a steep rise in the consumption of opioids in Canada in recent years. According to the Center for Diseases Control and Prevention 2020, in the United States, the overall opioid dispensing rate in 2020 was 43.3 prescriptions per 100 people. Thus increasing number of OIC prescriptions in the United States boot the market over the forecast period.

Furthermore, according to the study titled Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancerous pain published in the Future Medicine In June 2020, Naldemedine appears to be an effective and safe first-line therapy for the treatment of opioid-induced constipation in adults with chronic noncancer pain. Thus, rising product development in the country and several clinical studies are expected to boost the market in the region.

Competitive Landscape

The opioid-induced constipation treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca plc, Mallinckrodt Pharmaceuticals, Bausch Health (Salix Pharmaceuticals), Merck & Co Inc, Shionogi & Co Ltd, GlaxoSmithKline (Theravance Biopharma Inc), Takeda Pharmaceutical, Novartis AG (Sandoz), RedHill Biopharma, Pfizer, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the opioid-induced constipation treatment market globally. For instance, in January 2022, BioGaia Pharma reported First Patient Enrolled in the Phase II Clinical Study Evaluating BGP345A for the treatment of opioid-induced constipation (OIC-1).

AstraZeneca PLC

Overview:

The company focuses on the discovery, development, and commercialization of prescription medicines in Oncology and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. These pharmaceutical products are then manufactured, marketed, and sold.

Product Portfolio:

MOVANTIK: MOVANTIK is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.

Why Purchase the Report?

  • Visualize the composition of the global opioid-induced constipation treatment market segmentation by drug class, route of administration, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global opioid-induced constipation treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global opioid-induced constipation treatment market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global opioid-induced constipation treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Opioid-Induced Constipation Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Opioid-Induced Constipation Treatment Market -Market Definition and Overview

3. Global Opioid-Induced Constipation Treatment Market - Executive Summary

  • 3.1. Market Snippet By Drug Class
  • 3.2. Market snippet By Route of administration
  • 3.3. Market Snippet By Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Opioid-Induced Constipation Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rise in the availability of effective OIC drugs
      • 4.1.1.2. Rise in the Availability of Effective OIC Drugs Along with Growing Prevalence of Chronic Idiopathic Pains
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness about OIC among the patients
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Opioid-Induced Constipation Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Opioid-Induced Constipation Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. Global Opioid-Induced Constipation Treatment Market - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Mu-Opioid Receptor Antagonists*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Methylnaltrexone
    • 7.2.4. Naloxegol
    • 7.2.5. Naldemedine
    • 7.2.6. Others
  • 7.3. Chloride Channel Activators
    • 7.3.1. Lubiprostone
    • 7.3.2. Others

8. Global Opioid-Induced Constipation Treatment Market - By Route of administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 8.1.2. Market Attractiveness Index, By Route of administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Parenteral

9. Global Opioid-Induced Constipation Treatment Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Other

10. Global Opioid Induced Constipation Treatment Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Opioid Induced Constipation Treatment Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Opioid Induced Constipation Treatment Market - Company Profiles

  • 12.1. AstraZeneca plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Mallinckrodt Pharmaceuticals
  • 12.3. Bausch Heath (Salix Pharmaceuticals )
  • 12.4. Merck & Co Inc
  • 12.5. Shionogi & Co Ltd
  • 12.6. GlaxoSmithKline (Theravance Biopharma Inc)
  • 12.7. Takeda Pharmaceutical
  • 12.8. Novartis AG (Sandoz)
  • 12.9. Cubist Pharmaceuticals
  • 12.10. Pfizer, Inc.

LIST NOT EXHAUSTIVE

13. Global Opioid Induced Constipation Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us